CD274 and neoplasm: Wu et al. [52,53] hypothesize that lenvatinib may suppress HCC angiogenesis and antitumor immunity, potentially increasing the antiproliferative effect of PD-1 antibodies (not able alone to obtain adequate levels of anticancer immunity by PD-L1/PD-1 axis blockade) and counteracting the undesired neoangiogenic action of TACE (per se capable of increasing the efficacy of PD-1 antibodies through the release of tumor-specific antigens).